Biotech

0 925
Maxim Integrated Products Inc. MXIM Stock News

Maxim Integrated Products Inc. (NASDAQ: MXIM)

Maxim Integrated Products was off to what seemed like a relatively normal day. When the market opened, the stock was trading slightly in the green. From there, we saw a continuation of slow, yet steady movement upward. However, minutes ago, that slow movement turned into a spike upward. Below, we’ll talk about what we’re seeing from MXIM, why, and what we’ll be watching for with regard to the stock ahead.





What We’re Seeing From MXIM

As mentioned above, Maxim Integrated Products was off to a relatively strong day in the market early on. When the trading session opened, the stock was already trading in the green. From there, the stock worked its way further upward at a relatively slow pace. Nonetheless, minutes ago, that all changed minutes ago when the stock started screaming upward. Currently (10:22), MXIM is trading at $41.26 per share after a gain of $0.79 per share or 1.95% thus far today.

Why The Stock Is Spiking Upward

As soon as the spike started, we got the alert from Tradespoon that it was time to look at MXIM. When we did, the CNA Finance team started digging to see exactly what was causing the movement. In this particular case, it didn’t take long to dig up the story. While we were unable to find fundamental news that would lead to such gains, we were able to find an interesting rumor in the social space.


When you look into your favorite social network and search for Maxim Integrated Products, chances are that you will find the rumor too. The rumor is that the company is going to be taken over soon. However, it’s very vague. There is no suggestion with regard to who the buyer might be or what the price might be. Nonetheless, the rumor is definitely leading to excitement in the market.

What We’ll Be Watching Ahead

Moving forward, the CNA Finance team will be keeping a close eye on MXIM. In particular, we’re interested in learning more about whether or not there is any validity to these rumors. Nonetheless, we’ll be watching the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pexels]

0 3976
Transgenomic Inc TBIO Stock News

Transgenomic Inc (NASDAQ: TBIO)

Transgenomic is off to an incredibly strong start to the trading session today. In pre-market trading, the stock spiked more than 200%. While it has taken a bit of a dive since the opening bell, the stock is still trading on overwhelmingly impressive gains. Below, we’ll talk about what we’re seeing from TBIO, why, and what we’ll be watching for ahead.





What We’re Seeing From TBIO

As mentioned above, Transgenomic is having an overwhelmingly strong day in the market today. In pre-market trading, the stock climbed dramatically on news of a licensing agreement, which we’ll talk about later. When the opening bell rang, the stock was trading up well above 200%. However, since the bell, we’ve seen a bit of a correction. Currently (9:37), TBIO is trading at $0.85 per share after a gain of $0.56 per share (193.64%) thus far today.

Why The Stock Is Gaining

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on TBIO. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. It didn’t take long to uncover the story in this case. It seems as though the gains are being caused by the fact that the company has announced a licensing agreement.


Early on in the pre-market hours, Transgenomic announced that it had entered into a licensing agreement surrounding the company’s ICE COLD-PCR technology. According to the release, Canadian laboratory services provider, LifeLabs has chosen the company’s technology as its mutation enrichment platform for cancer testing. Of course, this made investors excited and sent the stock upward.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on TBIO. In particular, we’ll be watching for more licensing agreements to come down the line. After all, this was just one agreement, and we see what it can do to a stock. We’ll keep tabs on the news and be sure to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of The Blue Diamond Gallery]

0 2662
iShares NASDAQ Biotechnology Index (ETF) IBB News

iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB)

The iShares NASDAQ Biotechnology Index wasn’t off to the best of days in the market to begin with today. When the opening bell rang, the ETF was already in the red. From there, we saw some ups and downs, but the stock hasn’t been able to break into the green all day. Then, just minutes ago, Trump took center stage, causing it to fall further. Below, we’ll talk about what we’re seeing from IBB, why, and what we’ll be watching for ahead.





What We’re Seeing From IBB

As mentioned above, the iShares NASDAQ Biotechnology Index is having a horrible day in the market today. Early on, things didn’t look great, but they weren’t so bad either. At the opening bell, the ETF was trading slightly in the red. From there, we saw a struggle between the bears and the bulls as it worked to make it to the green. Unfortunately however, that battle was won by the bears minutes ago as the ETF started spiking dramatically in the downward direction. Currently (11:25), IBB is trading at $278.49 after a loss of $8.01, or 2.79%.

Why The ETF Is Down

As usual, our partners at Trade Ideas were the first to notify us of the downward spike on IBB. As soon as they did, the CNA Finance team went to work to figure out what was causing the movement. In this case, it didn’t take long to dig up the story. It seems as though the ETF is falling as a result of comments by Donald Trump.


Minutes ago, Trump took center stage to speak to the American people. One of the first topics of discussion was the pharmaceuticals industry. In his statements, he said that big pharma was “getting away with murder.” In particular, Trump is talking on the pricing side of things; we know, of course, the industry has been dealing with backlash in that area for some time. As a result, the iShares NASDAQ Biotech Index is taking a dive.

What We’ll be Watching For Ahead

Moving forward, the CNA Finance team will be watching IBB incredibly closely. In particular, we’re interested in Trump’s early moves as President of the United States and how those moves will affect the pharma sector as a whole. We’ll watch the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 837
ZIOPHARM Oncology ZIOP Stock News

ZIOPHARM Oncology Inc. (NASDAQ: ZIOP)

ZIOPHARM Oncology wasn’t off to the best of days in the market today. In fact, when the opening bell rang, the stock went on a mad dash toward the bottom. After a slight correction bringing it back to the breakeven point, we saw another slight dip. And then minutes ago, the stock started to soar. Below, we’ll talk about what we’re seeing, why, and what we’ll be watching for with regard to ZIOP ahead.





What We’re Seeing From ZIOP

As mentioned above, ZIOPHARM Oncology didn’t look like it was going to have a great day in the market early on. When the trading session started, the stock started falling. From there, most of the day has been spent in the red. While we’ve seen some ups and some downs, the stock just hasn’t been able to break into the green. That is, until minutes ago, when the stock started to spike. At the moment (10:48), ZIOP is trading at $6.01 per share after a gain of $0.18 per share (3.09%) thus far today.

Why The Stock Is Climbing

As is almost always the case, our friends at Trade Ideas were the first to inform us of the upward movement on ZIOP. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. In this case, it didn’t take long to dig up the story. It seems as though the gains are being caused by an announcement made at the JPM 2017 conference.


According to Adam Feuerstein, the company released a “Groundbreaking regulatory update.” The update is that the FDA has granted the company an end of Phase 2 meeting for II-12 gene therapy. According to this break, it seems as though ZIOPHARM Oncology may be able to jump from Phase 1 directly to Phase 3. Of course, investors are excited about the prospect.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ZIOP. In particular, we’ll be watching to see if the company is indeed able to jump from Phase 1 to Phase 3. Of course, if this proves to be the case, the work toward regulatory approval will move much quicker. We’ll be watching the news and bringing it to you as it breaks.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 1901
Biocept Inc BIOC Stock News

Biocept Inc (NASDAQ: BIOC)

Biocept is having an incredible day in the market today. This is following up on the large gains that we saw on the stock yesterday. Today, we are only minutes into the session. However, the stock is already trading on massive gains. After started the day off with gains of more than 50%, the stock seems to be heading further upward. Below, we’ll talk about what we’re seeing in the market, why, and what we’ll be watching for with regard to BIOC ahead.





What We’re Seeing From BIOC

As mentioned above, Biocept is having an overwhelmingly strong start to the trading session today. Following up on the gains we saw yesterday, the stock started the day with impressive profits. While we are only minutes into the session, it seems as though those profits are likely to continue, as the stock continues to head in the upward direction. At the moment (9:41), BIOC is trading at $2.93 per share after a gain of $1.12 per share (61.88%) thus far today.

Why The Stock Is Climbing

As was the case in the beginning of the run yesterday, our partners at Trade Ideas were the first to inform us of the gains on BIOC today. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. In our search, the answer quickly became clear. The gains that we’re seeing on BIOC today are a continuation of movement that we saw on the stock yesterday following a positive press release.


In the press release, investors learned that far more people will now have access to Biocept testing. In fact, we learned that the company has entered into a provider agreement with Blue Cross Blue Shield. That means that the company can now add customers of one of the largest insurance companies in the world to its growing audience.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on BIOC. In particular, we’re interested in seeing coming sales reports following this update. We’re also interested in seeing if any more provider agreements are to come down the line. We’ll be watching the news closely and bringing you the updates as they break!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required











[Image Courtesy of Pixabay]

0 1121
Sarepta Therapeutics SRPT Stock News

Sarepta Therapeutics Inc (NASDAQ: SRPT)

Sarepta Therapeutics didn’t look like it was going to have the best of days in the market today. While the stock was in the green at the start of the session, it went on a dash toward the bottom when the opening bell rang. However, minutes ago, things started to change for the stock in a big way as it started to spike upward. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to SRPT ahead.





What We’re Seeing From SRPT

As mentioned above, Sarepta Therapeutics didn’t look like it was off to the best of starts in the market today. Although the stock did start the day in the green, it didn’t take long to make it to the red after the opening bell. Nonetheless, minutes ago, the stock started to spike upward in a big way. At the moment (10:42), SRPT is trading at $36.22 per share after a gain of $4.96 per share (15.88%) thus far today.

Why The Stock Is Climbing

As is nearly always the case, our partners at Trade Ideas were the first to inform us of the gains on SRPT. As soon as they did, the CNA Finance team started digging to see what was causing the movement in the stock. In this case, it took no time at all to uncover the story. Minutes ago, the company released a business update that excited investors.


In the update, Sarepta Therapeutics offered several bits of positive news. First and foremost, the company generated $5.4 million through Exondys 51 in the fourth quarter. On top of that, they have received more than 250 start forms – more than 100 of them from physicians. Finally, the company explained that it is currently in active discussions with payers to expand the horizons of covered lives.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SRPT. In particular, we’ll be watching for further developments with regard to Exondys 51. If the company continues in this direction, there’s definitely more positive news to come. We’ll keep a close eye on the story and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 5589
EnteroMedics ETRM Stock News

EnteroMedics Inc (NASDAQ: ETRM)

EnteroMedics is having an interesting day in the market today. After starting the day off well in the green, the stock took a dive at the opening bell, bringing it into the red. However, that didn’t last long. Minutes ago, the stock started spiking yet again, adding to the massive gains that we’ve seen recently. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to ETRM ahead.





What We’re Seeing From ETRM

As mentioned above, EnteroMedics is in the midst of a wild ride in the market today. When the opening bell rang, the stock was trading well into the green. However, shortly after the opening bell, we saw a slide to the red. And then we saw big gains in the stock just minutes ago as yet another spike began. Currently (10:27), ETRM is trading at $19.41 per share after a gain of $1.71 per share (9.66%) thus far today.

Why The Stock Is Gaining

As usual, our partners at Trade Ideas were the first to inform us of the gains on ETRM. However, this isn’t the first time we’ve gotten this alert. The truth is that they’ve been lighting us up about the stock regularly over the past few sessions, and for good reason. The stock has been soaring in the market. The reason for this is simple.


Late last week, investors got great news from Enteromedics. The company’s flagship therapy, vBloc, had been successfully implanted at two more facilities. With the expansion of vBloc, it seems as though things are finally coming together for the company, and investors are excited. As a result, we’re seeing gains in the market in response.

What We’ll Be Watching Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ETRM. In particular, we’ll be watching for news with regard to further expansion, as it is clear that this is a key goal for the company. We’re also interested in learning more about sales volume at the current vBloc therapy locations. We’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 2234
Biocept Inc BIOC Stock News

Biocept Inc (NASDAQ: BIOC)

Biocept is having an overwhelmingly strong start to the trading session today. When the opening bell rang, the stock was relatively flat, where it stayed for a few minutes. However, it didn’t take long for the stock to start spiking. In fact, we’re 8 minutes into the session at the moment and the gains are already quite impressive. Below, we’ll talk about what we’re seeing in the market, why, and what we’ll be watching for with regard to BIOC ahead.





What We’re Seeing From BIOC

As mentioned above, Biocept is having an incredibly strong trading session thus far in the market today. When the opening bell rang, there wasn’t much movement. However, shortly after the bell, the stock started to make a mad-dash for the top. Currently (9:38), BIOC is trading at $1.17 per share after a gain of $0.15 per share (14.71%) thus far today.

Why The Stock Is Climbing

As is usually the case, our partners at Trade Ideas were the first to inform us of the run on BIOC. As soon as they did, the CNA Finance team started digging to see what was causing the movement. In this particular case, it didn’t take long to uncover the story. It seems as though the gains on the stock are the result of a positive PR that was released just minutes ago.


In the PR, we learned that Biocept has entered into a provider agreement with Blue Cross Blue Shield. Of course, this is overwhelmingly positive news, as the agreement will likely lead to far more business for the company.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on BIOC. In particular, we’ll be watching to see what the next steps are, now that the agreement is signed. We’re also interested in coming sales reports. Given the sheer size of Blue Cross Blue Shield, this could prove to be massive for BIOC. We’ll watch the news closely and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 1351
Pernix Therapeutics PTX Stock News

Pernix Therapeutics Holdings (NASDAQ: PTX)

Pernix Therapeutics is having yet another incredible day in the market today, following up on the gains that we saw late last week. Today, when the opening bell rang, the stock found itself well in the green. From there, we’ve seen some upward and some downward movement, but the stock is still trading with incredible profits. Below, we’ll talk about what we’re seeing in the market, why, and what we’ll be watching for ahead.





What We’re Seeing From PTX

As mentioned above, Pernix Therapeutics is having a strong day in the market today. This is following the gains that we saw on the stock toward the end of last week. Today, when the market opened, the stock was already trading with incredible profits. Nonetheless, we’re seeing quite a bit of movement. While some movement is up and some is down, the strong gains for the day seem to be here to stay. At the moment (12:36), PTX is trading at $3.36 per share after a gain of $0.45 per share (15.48%) thus far today.

Why The Stock Is Climbing

As usual, our partners at Trade Ideas were the first to inform us of the gains on PTX. As soon as they did, the CNA Finance team started digging for the cause of the gains. In this case, it didn’t take long to uncover the story. It seems as though the gains are being caused by an announcement that was made last week.


According to the announcement, Pernix Therapeutics recently appointed Ken Piña as General Counsel and Chief Compliance Officer. As a result of this hire, it is our opinion that investors have renewed hopes of a possible asset sale coming down the line. Nonetheless, this is clearly exciting news for investors considering the gains it has caused.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping close tabs on PTX. In particular, we’ll be watching to see what the new appointment means for the company. While we know changes will be made, we’re excited to see just what those changes are. We’ll be watching the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 1249
Eagle Test Systems Common Stock EGLT Stock News

Eagle Test Systems Common Stock (NASDAQ: EGLT)

Eagle Test Systems was off to what seemed to be a relatively normal day in the market today. When the opening bell rang, the stock was trading in the red. From there, it continued to fall for a few minutes before reversing. Soon enough, the stock made it to the green, but nothing about the movement was exciting. That is, until minutes ago when the stock started to soar. Below, we’ll talk about what we’re seeing in the market, why, and what we’ll be watching for with regard to EGLT ahead.





What We’re Seeing From EGLT

As mentioned above, Eagle Test Systems was off to what seemed to be a relatively normal day in the market today. As soon as the market opened, the stock went on a slow slide into the red. However, as the day progressed, a correction became clear, bringing the stock slightly in the green. Then,  minutes ago, the stock started gaining in a big way. At the moment (12:14), EGLT is trading at $8.96 per share after a gain of $1.06 per share (13.42%) thus far today.

Why The Stock Is Gaining

As is usually the case, our partners at Trade Ideas were the first to inform us of the upward movement on EGLT. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. In this case, it didn’t take long to dig up the story. It seems as though the gains have to do with news that was released by the FDA minutes ago.


In a note, the FDA has given great news to EGLT investors. They have approved a treatment. According to the announcement Eagle has received FDA approval for Arymo ER. For more details on the news, visit the FDA’s website here.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on EGLT. In particular, we’re interested in seeing what next steps the company will take following the approval. We’ll watch the news closely and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

Thought Leader Discussions

Josh Disbrow head shot1 (1)

0 1412
Aytu Bioscience Inc (OTCMKTS: AYTU) Recently, the CNA Finance team had an opportunity to speak with Josh Disbrow, CEO of Aytu Bioscience. Josh Disbrow has...